These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16097181)

  • 41. Medi-messages.
    Jeffrey LP
    Hosp Formul; 1982 Dec; 17(12):1664-5. PubMed ID: 10258760
    [No Abstract]   [Full Text] [Related]  

  • 42. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance.
    Godman B; Wettermark B; Hoffmann M; Andersson K; Haycox A; Gustafsson LL
    Expert Rev Pharmacoecon Outcomes Res; 2009 Feb; 9(1):65-83. PubMed ID: 19371180
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Role of drug information].
    Lunde PK
    Tidsskr Nor Laegeforen; 1977 Jan; 97(3):150-1. PubMed ID: 835120
    [No Abstract]   [Full Text] [Related]  

  • 44. Promoting rational drug use through the ASHP Commission on Therapeutics.
    Witmer DR
    Am J Hosp Pharm; 1994 Jun; 51(12):1536. PubMed ID: 8092154
    [No Abstract]   [Full Text] [Related]  

  • 45. Using clinical evidence to manage pharmacy benefits: experiences of six states.
    Bergman D; Hoadley J; Kaye N; Crowley J; Hostetter M
    Issue Brief (Commonw Fund); 2006 Mar; (899):1-14. PubMed ID: 16562357
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [A new model of drug committees' activities developed in Gothenburg].
    Iwarson S
    Lakartidningen; 1996 Jul; 93(30-31):2649-50. PubMed ID: 8765777
    [No Abstract]   [Full Text] [Related]  

  • 47. [Letter: The role of the National Board of Health and Welfare in drug information].
    Liljestrand A; Rosén A
    Lakartidningen; 1976; 73(20):1881-2. PubMed ID: 1271917
    [No Abstract]   [Full Text] [Related]  

  • 48. [Drug committees towards the regions. The Danish Society of Clinical Pharmacology].
    Reuther LØ; Brock B;
    Ugeskr Laeger; 2007 Mar; 169(12):1113. PubMed ID: 17394824
    [No Abstract]   [Full Text] [Related]  

  • 49. Economic impact of a pharmacy resident in an assisted living facility-based medication therapy management program.
    Maack B; Miller DR; Johnson T; Dewey M
    Ann Pharmacother; 2008 Nov; 42(11):1613-20. PubMed ID: 18940921
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Proposed drug-drug cost effectiveness methodology.
    Gagnon JP; Osterhaus JT
    Ann Pharmacother; 2006 Mar; 40(3):524-8. PubMed ID: 16507612
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Again new resuscitation guidelines (2006): justification, costs and potential confusion].
    Meertens JH; Monteban-Kooistra WE; Tulleken JE; Ligtenberg JJ; Zijlstra JG
    Ned Tijdschr Geneeskd; 2007 Aug; 151(34):1874-7. PubMed ID: 17902560
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacoeconomics: principles and relevance to the activities of drug and therapeutics committees.
    Hughes D; Reynolds DJ
    Clin Med (Lond); 2009 Oct; 9(5):490-2. PubMed ID: 19886115
    [No Abstract]   [Full Text] [Related]  

  • 53. [The role of the economic evaluation in the Pharmacoterapeutic Committees of the two hospital of third level].
    Gómez-Lumbreras A; Trapero-Bertran M
    Farm Hosp; 2018 Jul; 42(4):184-185. PubMed ID: 29959845
    [No Abstract]   [Full Text] [Related]  

  • 54. The investigational drug steering committee.
    Ratain MJ
    Clin Adv Hematol Oncol; 2007 Oct; 5(10):779-80. PubMed ID: 17998895
    [No Abstract]   [Full Text] [Related]  

  • 55. [Guidelines of the Pharmaceutical Benefits Board for health economics evaluations. Cost-efficiency analysis from a national perspective].
    Lundin D; Carlsson P; Levin LA; Persson U
    Lakartidningen; 2006 Nov 22-28; 103(47):3716-8. PubMed ID: 17212321
    [No Abstract]   [Full Text] [Related]  

  • 56. [Long way from evidence to clinical recommendations].
    Rehnqvist N
    Lakartidningen; 2001 Mar; 98(12):1355-6. PubMed ID: 11320782
    [No Abstract]   [Full Text] [Related]  

  • 57. [Rh-prophylaxis or not? Recommendations are wanted].
    Belfrage P
    Lakartidningen; 2000 Dec; 97(51-52):6014-5. PubMed ID: 11195437
    [No Abstract]   [Full Text] [Related]  

  • 58. [Five years with the Institute of Rational Pharmacotherapy].
    Kampmann JP
    Ugeskr Laeger; 2005 Jan; 167(2):169-71. PubMed ID: 15697129
    [No Abstract]   [Full Text] [Related]  

  • 59. Pharmacoeconomics and clinical practice guidelines. A survey of attitudes in Swedish formulary committees.
    Anell A; Svarvar P
    Pharmacoeconomics; 2000 Feb; 17(2):175-85. PubMed ID: 10947340
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The strategic interaction between firms and formulary committees: effects on the prices of new drugs.
    García-Alonso MD; García-Mariñoso B
    J Health Econ; 2008 Mar; 27(2):377-404. PubMed ID: 18276026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.